WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported second-quarter 2025 revenue of $12.7 million, driven by continued commercial momentum for its lead product, YCANTH®, and milestone payments from its Japanese partner, Torii Pharmaceutical.
Net revenue from YCANTH®, used to treat molluscum contagiosum, reached $4.5 million in the quarter, a 32.5% increase over Q1, supported by a 32.8% rise in dispensed applicator units to 13,434. Milestone revenue from Torii contributed an additional $8 million.
“I am pleased to report that the business momentum we experienced in the first quarter has continued into the second quarter of 2025,” said President and CEO Jayson Rieger, noting the increased adoption of YCANTH® and the company’s improved productivity following a restructuring last fall.
Verrica is also advancing its Phase 3 program for YCANTH® in common warts in collaboration with Torii, and anticipates a Japanese regulatory decision on YCANTH® (marketed there as TO-208) for molluscum contagiosum by year-end. Approval could trigger an additional $10 million milestone payment.
The company reported progress on VP-315, its investigational therapy for basal cell carcinoma. Following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration, Verrica is preparing to launch a pivotal Phase 3 program. VP-315 has shown positive proof-of-concept efficacy data, and Verrica is exploring strategic, non-dilutive financing options to fund development and potential commercialization.
Rieger described the basal cell carcinoma program as a “multiple billion-dollar opportunity” and said the company expects to share additional genomic and immune response data later this year at a scientific conference.
With late-stage pipeline catalysts and sustained growth in its commercial business, Verrica sees a path to “strong and sustainable growth” in the coming quarters.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.